Technetium (99mTc) exametazime
(Redirected from HMPAO)
Jump to navigation
Jump to search
 | |
| Clinical data | |
|---|---|
| Trade names | Ceretec |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C13H25N4O3Tc |
| Molar mass | 383.37 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | racemic |
| |
  (what is this?) (verify) | |
Technetium (99mTc) exametazime is a radiopharmaceutical sold under the trade name Ceretec, and is used by nuclear medicine physicians for the detection of altered regional cerebral perfusion in stroke[1] and other cerebrovascular diseases. It can also be used for the labelling of leukocytes to localise intra-abdominal infections[2] and inflammatory bowel disease.[3] Exametazime (the part without technetium) is sometimes referred to by its chemical name of hexamethylpropyleneamine oxime or HMPAO.
Chemistry[edit]
The drug consists of exametazime as a chelating agent for the radioisotope technetium-99m. Both enantiomeric forms of exametazime are used—the drug is racemic.[4] The third stereoisomer of this structure, the meso form, is not included.
References[edit]
- ^ Moretti, J. L.; Defer, G.; Cinotti, L.; Cesaro, P.; Degos, J. D.; Vigneron, N.; Ducassou, D.; Holman, B. L. (1990). ""Luxury perfusion" with 99mTc-HMPAO and 123I-IMP SPECT imaging during the subacute phase of stroke". European journal of nuclear medicine. 16 (1): 17–22. doi:10.1007/BF01566007. PMID 2307169.
- ^ Weldon, M. J.; Joseph, A. E.; French, A.; Saverymuttu, S. H.; Maxwell, J. D. (1995). "Comparison of 99m technetium hexamethylpropylene-amine oxime labelled leucocyte with 111-indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intra-abdominal abscess". Gut. 37 (4): 557–564. doi:10.1136/gut.37.4.557. PMC 1382910. PMID 7489945.
- ^ Ui, K.; Yamaguchi, T. (1991). "Therapy and diagnosis of emergency shock patients". Nihon Naika Gakkai zasshi. the Journal of the Japanese Society of Internal Medicine. 80 (12): 1892–1896. PMID 1804909.
- ^ Monography in the European Pharmacopoeia
External links[edit]
- European Association of Nuclear Medicine: Ceretec
- GE Healthcare: Ceretec
- Exametazime ligand: CID 9552071 from PubChem
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
